132 related articles for article (PubMed ID: 16936701)
21. Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3.
Subramaniam A; Shanmugam MK; Ong TH; Li F; Perumal E; Chen L; Vali S; Abbasi T; Kapoor S; Ahn KS; Kumar AP; Hui KM; Sethi G
Br J Pharmacol; 2013 Oct; 170(4):807-21. PubMed ID: 23848338
[TBL] [Abstract][Full Text] [Related]
22. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
Gu FM; Li QL; Gao Q; Jiang JH; Huang XY; Pan JF; Fan J; Zhou J
World J Gastroenterol; 2011 Sep; 17(34):3922-32. PubMed ID: 22025881
[TBL] [Abstract][Full Text] [Related]
23. ERK1/2 mediate wounding- and G-protein-coupled receptor ligands-induced EGFR activation via regulating ADAM17 and HB-EGF shedding.
Yin J; Yu FS
Invest Ophthalmol Vis Sci; 2009 Jan; 50(1):132-9. PubMed ID: 18658095
[TBL] [Abstract][Full Text] [Related]
24. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells.
Saxena NK; Sharma D; Ding X; Lin S; Marra F; Merlin D; Anania FA
Cancer Res; 2007 Mar; 67(6):2497-507. PubMed ID: 17363567
[TBL] [Abstract][Full Text] [Related]
25. BRaf and MEK inhibitors differentially regulate cell fate and microenvironment in human hepatocellular carcinoma.
Breunig C; Mueller BJ; Umansky L; Wahl K; Hoffmann K; Lehner F; Manns MP; Bantel H; Falk CS
Clin Cancer Res; 2014 May; 20(9):2410-23. PubMed ID: 24573550
[TBL] [Abstract][Full Text] [Related]
26. The tyrosine phosphorylated pro-survival form of Fas intensifies the EGF-induced signal in colorectal cancer cells through the nuclear EGFR/STAT3-mediated pathway.
Ta NL; Chakrabandhu K; Huault S; Hueber AO
Sci Rep; 2018 Aug; 8(1):12424. PubMed ID: 30127519
[TBL] [Abstract][Full Text] [Related]
27. Cyclosporin A activates human hepatocellular carcinoma (HepG2 cells) proliferation: implication of EGFR-mediated ERK1/2 signaling pathway.
Abo-El Fetoh ME; Helal GK; Saleh IG; Ewees M; ElShafey M; Elnagar MR; Akool ES
Naunyn Schmiedebergs Arch Pharmacol; 2020 May; 393(5):897-908. PubMed ID: 31907582
[TBL] [Abstract][Full Text] [Related]
28. Diosgenin, a steroidal saponin, inhibits STAT3 signaling pathway leading to suppression of proliferation and chemosensitization of human hepatocellular carcinoma cells.
Li F; Fernandez PP; Rajendran P; Hui KM; Sethi G
Cancer Lett; 2010 Jun; 292(2):197-207. PubMed ID: 20053498
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms involved in PGE2-induced transactivation of the epidermal growth factor receptor in MH1C1 hepatocarcinoma cells.
Tveteraas IH; Müller KM; Aasrum M; Ødegård J; Dajani O; Guren T; Sandnes D; Christoffersen T
J Exp Clin Cancer Res; 2012 Sep; 31(1):72. PubMed ID: 22967907
[TBL] [Abstract][Full Text] [Related]
30. Differential constitutive activation between STAT-related proteins and MAP kinase in primary acute myelogenous leukaemia.
Hayakawa F; Towatari M; Iida H; Wakao H; Kiyoi H; Naoe T; Saito H
Br J Haematol; 1998 Jun; 101(3):521-8. PubMed ID: 9633897
[TBL] [Abstract][Full Text] [Related]
31. The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma.
Steinway SN; Dang H; You H; Rountree CB; Ding W
PLoS One; 2015; 10(5):e0128159. PubMed ID: 26000702
[TBL] [Abstract][Full Text] [Related]
32. Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC).
Mukohara T; Kudoh S; Yamauchi S; Kimura T; Yoshimura N; Kanazawa H; Hirata K; Wanibuchi H; Fukushima S; Inoue K; Yoshikawa J
Lung Cancer; 2003 Aug; 41(2):123-30. PubMed ID: 12871775
[TBL] [Abstract][Full Text] [Related]
33. Phosphorylation of cMet tyrosine residues in murine ascitic hepatic cancer cell lines with different lymph node metastatic potentials.
Li Y; Huang X; Zhang Q; Ma K
Mol Med Rep; 2013 Aug; 8(2):655-61. PubMed ID: 23778885
[TBL] [Abstract][Full Text] [Related]
34. EGFR and HER2-Akt-mTOR signaling pathways are activated in subgroups of salivary gland carcinomas.
Suzuki S; Dobashi Y; Minato H; Tajiri R; Yoshizaki T; Ooi A
Virchows Arch; 2012 Sep; 461(3):271-82. PubMed ID: 22828828
[TBL] [Abstract][Full Text] [Related]
35. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
[TBL] [Abstract][Full Text] [Related]
36. Protein kinase R modulates c-Fos and c-Jun signaling to promote proliferation of hepatocellular carcinoma with hepatitis C virus infection.
Watanabe T; Hiasa Y; Tokumoto Y; Hirooka M; Abe M; Ikeda Y; Matsuura B; Chung RT; Onji M
PLoS One; 2013; 8(7):e67750. PubMed ID: 23844083
[TBL] [Abstract][Full Text] [Related]
37. A role for the epidermal growth factor receptor signaling in development of intestinal serrated polyps in mice and humans.
Bongers G; Muniz LR; Pacer ME; Iuga AC; Thirunarayanan N; Slinger E; Smit MJ; Reddy EP; Mayer L; Furtado GC; Harpaz N; Lira SA
Gastroenterology; 2012 Sep; 143(3):730-740. PubMed ID: 22643351
[TBL] [Abstract][Full Text] [Related]
38. Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells.
Chang AY; Wang M
BMC Cancer; 2013 May; 13():267. PubMed ID: 23721490
[TBL] [Abstract][Full Text] [Related]
39. [Ponatinib inhibits the proliferation of SNU-449 human hepatocellular cancer cells and blocks MAPK and PDK1/AKT/mTOR signaling pathways].
Liu C; Pei J; Mu X; Yu B; Gong T; Liang W
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 May; 38(5):425-431. PubMed ID: 35603651
[TBL] [Abstract][Full Text] [Related]
40. Cx32 exerts anti-apoptotic and pro-tumor effects via the epidermal growth factor receptor pathway in hepatocellular carcinoma.
Xiang Y; Wang Q; Guo Y; Ge H; Fu Y; Wang X; Tao L
J Exp Clin Cancer Res; 2019 Apr; 38(1):145. PubMed ID: 30947731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
